Matches in Nanopublications for { ?s ?p "[Furthermore, in vivo administration of GM-CSF at 60 microg/kg body weight daily for 5 consecutive days beginning immediately after injury decreased infarction volume, altered the expression of several apoptosis-related genes (Bcl-2, Bax, caspase 3, and p53), and improved locomotor behavior in the focal cerebral ischemia model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 12 of
12
with 100 items per page.
- NP316649.RAchkU-mijuVcXcMWJdzTMUxOl8s7xNOS6CPzf6rPopp4130_assertion description "[Furthermore, in vivo administration of GM-CSF at 60 microg/kg body weight daily for 5 consecutive days beginning immediately after injury decreased infarction volume, altered the expression of several apoptosis-related genes (Bcl-2, Bax, caspase 3, and p53), and improved locomotor behavior in the focal cerebral ischemia model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP316649.RAchkU-mijuVcXcMWJdzTMUxOl8s7xNOS6CPzf6rPopp4130_provenance.
- NP322790.RAeheesNjRwd04nEuEn3roF-ne-AcQQUTdNLw0xDHJh2I130_assertion description "[Furthermore, in vivo administration of GM-CSF at 60 microg/kg body weight daily for 5 consecutive days beginning immediately after injury decreased infarction volume, altered the expression of several apoptosis-related genes (Bcl-2, Bax, caspase 3, and p53), and improved locomotor behavior in the focal cerebral ischemia model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP322790.RAeheesNjRwd04nEuEn3roF-ne-AcQQUTdNLw0xDHJh2I130_provenance.
- NP161541.RAk-uG3rJGbwwtQR6CI0p6RstSmTcgu5BjMUm1YPHf_58130_assertion description "[Furthermore, in vivo administration of GM-CSF at 60 microg/kg body weight daily for 5 consecutive days beginning immediately after injury decreased infarction volume, altered the expression of several apoptosis-related genes (Bcl-2, Bax, caspase 3, and p53), and improved locomotor behavior in the focal cerebral ischemia model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP161541.RAk-uG3rJGbwwtQR6CI0p6RstSmTcgu5BjMUm1YPHf_58130_provenance.
- NP308237.RAcyvY3CAJHip4FoErDkY1UfSEJ_Lwlb2CoVO8cgwRJSg130_assertion description "[Furthermore, in vivo administration of GM-CSF at 60 microg/kg body weight daily for 5 consecutive days beginning immediately after injury decreased infarction volume, altered the expression of several apoptosis-related genes (Bcl-2, Bax, caspase 3, and p53), and improved locomotor behavior in the focal cerebral ischemia model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP308237.RAcyvY3CAJHip4FoErDkY1UfSEJ_Lwlb2CoVO8cgwRJSg130_provenance.
- NP281457.RAcJ-VDfFINb5-hXEpFvmrftxnsV0xTAbTZLB1F4Fbuqg130_assertion description "[Furthermore, in vivo administration of GM-CSF at 60 microg/kg body weight daily for 5 consecutive days beginning immediately after injury decreased infarction volume, altered the expression of several apoptosis-related genes (Bcl-2, Bax, caspase 3, and p53), and improved locomotor behavior in the focal cerebral ischemia model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP281457.RAcJ-VDfFINb5-hXEpFvmrftxnsV0xTAbTZLB1F4Fbuqg130_provenance.
- assertion description "[Furthermore, in vivo administration of GM-CSF at 60 microg/kg body weight daily for 5 consecutive days beginning immediately after injury decreased infarction volume, altered the expression of several apoptosis-related genes (Bcl-2, Bax, caspase 3, and p53), and improved locomotor behavior in the focal cerebral ischemia model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Furthermore, in vivo administration of GM-CSF at 60 microg/kg body weight daily for 5 consecutive days beginning immediately after injury decreased infarction volume, altered the expression of several apoptosis-related genes (Bcl-2, Bax, caspase 3, and p53), and improved locomotor behavior in the focal cerebral ischemia model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Furthermore, in vivo administration of GM-CSF at 60 microg/kg body weight daily for 5 consecutive days beginning immediately after injury decreased infarction volume, altered the expression of several apoptosis-related genes (Bcl-2, Bax, caspase 3, and p53), and improved locomotor behavior in the focal cerebral ischemia model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Furthermore, in vivo administration of GM-CSF at 60 microg/kg body weight daily for 5 consecutive days beginning immediately after injury decreased infarction volume, altered the expression of several apoptosis-related genes (Bcl-2, Bax, caspase 3, and p53), and improved locomotor behavior in the focal cerebral ischemia model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP731926.RA7oZsNTr9n0bSE1ziwMBGS0B24RD3dHu4PkTxwCfNTNE130_assertion description "[Furthermore, in vivo administration of GM-CSF at 60 microg/kg body weight daily for 5 consecutive days beginning immediately after injury decreased infarction volume, altered the expression of several apoptosis-related genes (Bcl-2, Bax, caspase 3, and p53), and improved locomotor behavior in the focal cerebral ischemia model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP731926.RA7oZsNTr9n0bSE1ziwMBGS0B24RD3dHu4PkTxwCfNTNE130_provenance.
- NP280915.RAJBkuyd7G0LMyn6m0ZpHgG5K_QMwL8sQaj9ceA7W4ROc130_assertion description "[Furthermore, in vivo administration of GM-CSF at 60 microg/kg body weight daily for 5 consecutive days beginning immediately after injury decreased infarction volume, altered the expression of several apoptosis-related genes (Bcl-2, Bax, caspase 3, and p53), and improved locomotor behavior in the focal cerebral ischemia model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP280915.RAJBkuyd7G0LMyn6m0ZpHgG5K_QMwL8sQaj9ceA7W4ROc130_provenance.
- NP731924.RAvXDt-sv06vWOUa4l20-pQK39AW7KGAuFLMSU7gFttnk130_assertion description "[Furthermore, in vivo administration of GM-CSF at 60 microg/kg body weight daily for 5 consecutive days beginning immediately after injury decreased infarction volume, altered the expression of several apoptosis-related genes (Bcl-2, Bax, caspase 3, and p53), and improved locomotor behavior in the focal cerebral ischemia model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP731924.RAvXDt-sv06vWOUa4l20-pQK39AW7KGAuFLMSU7gFttnk130_provenance.